Alloimmunization in sickle cell disease: Changing antibody specificities and association with chronic pain and decreased survival

Transfusion

Volumn 55, Issue 6, 2015, Pages 1378-1387

  Telen, Marilyn J ^a   Afenyi Annan, Araba ^a   Garrett, Melanie E ^b   Combs, Martha R ^b   Orringer, Eugene P ^c   Ashley Koch, Allison E ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY; FERRITIN; HEMOGLOBIN; NARCOTIC AGENT; AUTOANTIBODY;

ADULT; ALLOIMMUNIZATION; ANTIBODY SPECIFICITY; ARTICLE; AVASCULAR NECROSIS; BLOOD TRANSFUSION; CHRONIC PAIN; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MULTIPLE ORGAN FAILURE; PHENOTYPE; SICKLE CELL ANEMIA; SURVIVAL; ADVERSE EFFECTS; BLOOD; COMPLICATION; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; ANTIBODY SPECIFICITY; AUTOANTIBODIES; BLOOD TRANSFUSION; CHRONIC PAIN; FEMALE; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84931572146     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12940     Document Type: Article

References (32)

1. Telen MJ,. Principles and problems of transfusion in sickle cell disease. Semin Hematol 2001; 38: 315-323.
2. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91: 1000-1005.
3. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617-1621.
4. King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 1997; 37: 376-381.
5. Win N, New H, Lee E, et al. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008; 48: 1231-1238.
6. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol 1999; 104: 189-194.
7. Garratty G,. Autoantibodies induced by blood transfusion. Transfusion 2004; 44: 5-9.
8. Young PP, Uzieblo A, Trulock E, et al. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004; 44: 67-72.
9. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431-1437.
10. Moreira Junior G, Bordin JO, Kuroda A, et al. Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil. Am J Hematol 1996; 52: 197-200.
11. Sela M,. Antigenicity: some molecular aspects. Science 1969; 166: 1365-1374.
12. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86: 776-783.
13. Murao M, Viana MB,. Risk factors for alloimmunization by patients with sickle cell disease. Braz J Med Biol Res 2005; 38: 675-682.
14. Hendrickson JE, Hod EA, Perry JR, et al. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion 2012; 52: 214-216.
15. Alarif L, Castro O, Ofosu M, et al. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin Immunol Immunopathol 1986; 38: 178-183.
16. Hoppe C, Klitz W, Vichinsky E, et al. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol 2009; 84: 462-464.
17. Zimring JC, Hendrickson JE,. The role of inflammation in alloimmunization to antigens on transfused red blood cells. Curr Opin Hematol 2008; 15: 631-635.
18. Tatari-Calderone Z, Minniti CP, Kratovil T, et al. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol 2009; 47: 64-70.
19. Gil KM, Abrams MR, Phillips G, et al. Sickle cell disease pain: relation of coping strategies to adjustment. J Consult Clin Psychol 1989; 57: 725-731.
20. Gil KM, Abrams MR, Phillips G, et al. Sickle cell disease pain: 2. Predicting health care use and activity level at 9-month follow-up. J Consult Clin Psychol 1992; 60: 267-273.
21. Wison Schaeffer JJ, Gil KM, Burchinal M, et al. Depression, disease severity, and sickle cell disease. J Behav Med 1999; 22: 115-126.
22. Afenyi-Annan A, Kail M, Combs MR, et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 2008; 48: 917-924.
23. Miller ST, Kim HY, Weiner DL, et al. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013; 53: 704-709.
24. Natukunda B, Schonewille H, Ndugwa C, et al. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion 2010; 50: 20-25.
25. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-1071.
26. O'Suoji C, Liem RI, Mack AK, et al. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer 2013; 60: 1487-1491.
27. Niscola P, Sorrentino F, Scaramucci L, et al. Pain syndromes in sickle cell disease: an update. Pain Med 2009; 10: 470-480.
28. Tendas A, Scaramucci L, Giovannini M, et al. Pain in blood cancers. Indian J Palliat Care 2011; 17: 175-183.
29. Sogutlu A, Levenson JL, McClish DK, et al. Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES Project. Psychosomatics 2011; 52: 272-279.
30. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain 2009; 145: 246-251.
31. Oliveira MC, Mendonça TF, Vasconcelos LR, et al. Association of the MBL2 gene exon1 polymorphism and vasoocclusive crisis in patients with sickle cell anemia. Acta Haematol 2009; 121: 212-215.
32. Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006; 12: 1269-1277.